Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
2019 |
| gptkbp:ATCCode |
B06AX06
|
| gptkbp:CASNumber |
1610762-09-8
|
| gptkbp:developedBy |
gptkb:Novartis
|
| https://www.w3.org/2000/01/rdf-schema#label |
crizanlizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
humanized IgG2 kappa antibody
|
| gptkbp:marketedAs |
gptkb:Adakveo
|
| gptkbp:mechanismOfAction |
inhibits P-selectin-mediated cell adhesion
|
| gptkbp:reduces |
frequency of vaso-occlusive crises
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea back pain arthralgia |
| gptkbp:target |
gptkb:P-selectin
|
| gptkbp:UNII |
6Z5F4XW6F2
|
| gptkbp:usedFor |
sickle cell disease
|
| gptkbp:bfsParent |
gptkb:Adakveo
|
| gptkbp:bfsLayer |
6
|